Completed
An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-10-28
85
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
N
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
B
Biogen
Collaborating Sponsor
AI-Summary
What this Trial Is About
To determine the maximal safe daily dose of BG8962 (rCD4) which can be administered by continuous subcutaneous infusion (CSCI) over 24 hours; to determine the pharmacokinetics of BG8962 when it is administered by intramuscular and subcutaneous routes; and to look for dose related antiviral activity determined by quantitation of infectious HIV peripheral blood leukocytes (PBLs) and plasma, and by monitoring the blood levels of viral p24 antigen (when present), CD4+ T-cells, and Beta-2- microglobulin. Recombinant soluble CD4 protein (rCD4) is a drug that has been produced by genetic engineering techniques. In laboratory studies, rCD4 binds to HIV and reduces its ability to enter the cell, thus inhibiting its reproduction. Before rCD4 can be tested for therapeutic effectiveness in HIV-infected patients, it is necessary to determine the maximum dose that can be tolerated by humans. AMENDED: To date, Biogen's original sequence recombinant soluble CD4 and Biogen's natural sequence recombinant soluble CD4 have both been referred to as recombinant soluble CD4 (rsCD4). In order to distinguish between these two products, a change in nomenclature has been made. In this protocol, whenever the original sequence CD4 molecule is referred to, it is called recombinant soluble T4 (rsT4). Whenever the natural sequence molecule (currently under study in this protocol) is referred to, it is called BG8962 or rCD4. Whenever the drug is discussed generically, it is referred to as rsCD4.
CONDITIONS
Official Title
An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive
Who Can Participate
Eligibility Criteria
You may qualify if you...
Inclusion Criteria
Concurrent Medication:
Allowed:
- Nystatin or clotrimazole for suppression of oral thrush.
- Aerosolized pentamidine for Pneumocystis prophylaxis in Group A patients.
- Trimethoprim / sulfamethoxazole for Pneumocystis prophylaxis in patients who are hematologically stable on trimethoprim / sulfamethoxazole.
Patients must have:
- Group A: AIDS and symptoms defined in disease status.
- Group B: AIDS related complex (ARC) and symptoms defined in disease status.
Exclusion Criteria
Co-existing Condition:
Patients with the following disease or conditions are excluded:
- Malignancies other than Kaposi's sarcoma.
- AIDS dementia.
- Opportunistic infections requiring ongoing therapy except oral thrush suppression with nystatin or clotrimazole or Pneumocystis prophylaxis in Group A patients.
- Significant organ system dysfunction including:
- Granulocytopenia with a granulocyte count < 1000 cells/mm3.
- Thrombocytopenia - < 75000 platelets/mm3.
- Anemia with a hemoglobin < 9.5 g/dl.
- Renal dysfunction - creatinine > 2 mg/dl.
- Hepatic dysfunction with enzymes or bilirubin > 3 x upper limit of normal.
Patients with the following are excluded:
- Preexisting antibodies to rCD4.
- Malignancies other than Kaposi's sarcoma.
- AIDS-dementia complex.
- Opportunistic infections requiring ongoing therapy.
- Significant organ system dysfunction.
- Inability to sign voluntarily the consent form.
Prior Medication:
Excluded:
- Recombinant soluble CD4 protein (rCD4).
- Excluded within 30 days of study entry:
- Immunomodulatory therapy or agent with anti-HIV activity.
- Chemotherapy.
Prior Treatment:
Excluded within 30 days of study entry:
- Radiotherapy.
Active illicit drug use or alcohol abuse at time of entry.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Total: 1 location
1
Stanford CRS
Palo Alto, California, United States, 943055107
Status Unknown
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Similar Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here